Swedish Orphan Biovitrum is a specialized international biopharmaceutical company focused on developing and commercializing medicines for rare and debilitating diseases. The company’s portfolio is concentrated in three therapeutic areas: Haematology, Immunology, and Specialty Care. Key products include Elocta and Alprolix for the treatment of haemophilia, Kineret for autoinflammatory diseases, and Orfadin for hereditary tyrosinemia type 1. Sobi also holds rights to Kepivance for oral mucositis and recently received market authorization for Altuvoct. The company operates globally, serving patients and healthcare systems in Europe, North America, Australia, New Zealand, and Japan. Sobi was formed in 2010 through the acquisition of Swedish Orphan International by Biovitrum, uniting Swedish Orphan’s orphan drug portfolio with Biovitrum’s manufacturing and haemophilia franchise. The company’s origins trace back to the 1930s as a subsidiary of Kärnbolaget Aktiebolag Biokemisk Industri, evolving through name changes to Kabi and KabiVitrum before the 2001 formation of Biovitrum. Strategic partnerships include collaborations with Sanofi for extended half-life factor products and Affibody AB for interleukin-1 therapies. Sobi also engages in humanitarian aid programs, such as donating haemophilia clotting factor therapy through the World Federation of Hemophilia.

Summarised from the company's own disclosures, fiscal year ended Dec 2024

Industry Biotechnology Homepage sobi.com
Sector Healthcare IR page sobi.com/en
Tags
rare diseases, haemophilia, haematology, immunology, autoinflammatory diseases, orphan drugs, recombinant proteins, biopharmaceuticals, specialty care, humanitarian aid, Elocta, Alprolix, Kineret, Orfadin, Kepivance, Altuvoct, Genotropin, ReFacto, KabiPen, AHF concentrate Kabi, Swedish Orphan, Biovitrum, Kabi, KabiVitrum, Affibody, Sanofi, Pfizer, Wyeth, Genentech, World Federation of Hemophilia
Press page sobi.com/en/press-releases

Metrics

Valuation  
Market cap kr 166.166B
Market cap (USD) $ 16.356B
P/E 349.82
PEG —
P/BV 4.41
P/S 18.18
P/OCF 79.49
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.2%
ROI 1.1%
ROIC 1.1%
Profit margin 1.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -43.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 13.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 127
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 28.238B 26.027B 22.123B 18.79B 15.529B 15.261B 14.248B 9.139B 6.511B 5.204B 2.607T 2.607B 2.177B 1.923B 1.911B 1.907B 1.297B
Net profit 478M 3.879B 2.409B 2.638B 2.679B 3.245B 3.304B 2.418B 1.149B 854M -267.832B -267.832M -92.956M -100.883M 17.927M -104.451M 32.5M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price — 105 266.68 215.86 185.23 — 154.67 192.86 120.4 107.72 — — — — — — —
Price performance 12m — -0.61 0.24 0.17 0.11 — -0.2 0.6 0.12 — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Balance sheet detail
Trade receivables (SEK) — 3.76B 3.44B 5.25B 5.17B 5.2B
↳ YoY growth -8.4% +52.6% -1.5% +0.5%
Other receivables (SEK) — 465M 345M 558M 602M 405M
Borrowings, current (SEK) — 4.02B 1.77B 5.8B 8.81B 3.93B
Borrowings, non-current (SEK) — 10.1B 8.78B 2.97B 11.4B 12.4B
Lease liabilities (SEK) — 419M 361M 334M 316M 402M
Cash and deposits (SEK) 737M 404M 1.05B 1.36B 904M 1.14B
Net debt (borrowings + leases - cash) (SEK) — 14.2B 9.86B 7.74B 19.6B 15.6B
Cash flow detail
Operating cash flow (SEK) — 4.93B 5.47B 4.67B 4.47B 7.39B
Purchases of property, plant and equipment (SEK) — -41M -47M -72M -407M -170M
Purchases of intangible assets (SEK) — -3.81B -323M -1.41B -4.54B -2.84B
Change in receivables (cash effect) (SEK) — -185M 452M -1.98B -900M -178M
Change in inventories (cash effect) (SEK) — -1.33B -318M 413M 286M -159M
Change in payables (cash effect) (SEK) — 1.07B 980M 763M -546M 157M
Interest paid (cash effect) (SEK) — -333M -324M -309M -949M -1.09B
Income taxes paid (cash effect) (SEK) — -918M -1.12B -673M -641M -307M
Share-based compensation (SEK) — — — 172M 194M 218M
Operating cash flow before change in receivables (SEK) — 5.11B 5.02B 6.65B 5.37B 7.57B
Free cash flow (OCF - PPE - intangibles) (SEK) — 1.07B 5.1B 3.19B -473M 4.38B
Income detail
Research and development expense (SEK) — 1.59B 1.99B 2.35B 2.8B 3.54B
Total comprehensive income (SEK) — 3.19B 2.87B 3.05B 1.69B 5.75B
Comprehensive income to owners (SEK) — — — — 1.69B 5.76B
Reported — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

29 October, 2026 08:00

Detailed efficacy and safety results from the pivotal phase 3 study demonstrate statistically significant serum urate reductions through 12 months

Pozdeutinurad is an investigational, once-daily, highly selective URAT1 inhibitor

Sobi® (STO: SOBI) today announced the presentation of late-breaking data from the pivotal Phase 3 REDUCE-2 study of pozdeutinurad (AR882), an investigational next-generation once-daily oral, highly selective URAT1 inhibitor, at ACR Convergence 2026. The findings demonstrate clinically meaningful and durable reductions in serum urate (SU) levels through 12 months, with significantly more patients achieving target SU levels compared with placebo and a safety profile generally comparable to placebo. REDUCE-2 is part of the Phase 3 clinical programme evaluating pozdeutinurad in patients with uncontrolled gout.

In the global Phase 3 REDUCE-2 study, 811 patients with gout were randomised to receive pozdeutinurad 75 mg, pozdeutinurad 50 mg or placebo. The study met its primary endpoint, with 69.2% and 56.6% of patients receiving pozdeutinurad 75 mg and 50 mg, respectively, achieving SU levels below 6 mg/dL at month 6, compared with 8.1% of patients receiving placebo (both p<0.0001). Clinically meaningful reductions in serum urate were observed as early as month 1 and were sustained through month 12. At each assessment during the 12-month period, a greater proportion of patients treated with pozdeutinurad achieved SU levels below 6, 5, 4 and 3 mg/dL compared with placebo.

The incidence of treatment-emergent adverse events (TEAEs) was similar across treatment groups, occurring in 60.7%, 61.7% and 60.9% of patients receiving pozdeutinurad 75 mg, pozdeutinurad 50 mg and placebo, respectively.

"Achieving and maintaining target serum urate levels is fundamental to effective gout management, yet many patients remain inadequately controlled with currently available oral therapies, which can lead to permanent joint and tissue damage," said Puja P. Khanna, MD, MPH, Professor of Medicine in the Division of Rheumatology at the University of Michigan and investigator in the REDUCE-2 study. "The REDUCE-2 results demonstrated clinically meaningful and durable serum urate lowering over 12 months, with a safety profile comparable to placebo, supporting the potential of pozdeutinurad as a treatment option for patients living with uncontrolled gout."

“The presentation of these late-breaking Phase 3 data for the first time marks an important milestone in our efforts to advance innovation in gout,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. “The consistency of the results across both evaluated doses together with the sustained serum urate lowering through 12 months are encouraging as we continue advancing the programme for patients who need additional treatment options.”

Presentation details

Title: (LB20) Treatment with URAT1 Inhibitor Pozdeutinurad (AR882) in a Phase 3, Double-Blind, Randomized Study Lowers Serum Urate Levels in Participants with Gout

Presenter: Puja P. Khanna, MD, MPH

Date: Wednesday, November 11, 2026

Time: 8:15 AM – 8:30 AM ET

Location: Chapin Theater

About gout
Gout is the most common form of systemic inflammatory arthritis[i] . Elevated serum urate (SU) levels can lead to the accumulation of monosodium urate crystals in joints and other tissues, causing flares, joint damage and intense pain[ii] . Uncontrolled gout is a systemic, progressive disease characterised by SU levels above 6 mg/dL and persistent, debilitating clinical manifestations, including flares and/or tophi, despite treatment with oral urate-lowering therapies[iii] ,[iv] . Elevated SU levels have also been associated with cardiovascular, renal and metabolic diseases. Sustained serum urate (SU) lowering is central to gout management, promoting dissolution of monosodium urate crystals, limiting further crystal deposition, and reducing gout symptoms. 

About pozdeutinurad
Pozdeutinurad (AR882) is an investigational once daily oral, highly selective URAT1 inhibitor being developed to treat uncontrolled gout. Phase 2 studies demonstrated clinically significant efficacy with a sustained reduction of serum urate (SU) levels, dissolution of tophi and a generally well-tolerated safety profile. Pozdeutinurad is being evaluated in more than 800 patients, in two 12-month, randomised, double-blind, placebo-controlled Phase 3 studies, REDUCE 1 and REDUCE 2, assessing its ability to reduce SU in patients with uncontrolled gout.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn .
 

29 October, 2026 19:45

The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi**®) proposes that** Börje Ekholm is elected as new Board member and Chair of the Board at the 2027 Annual General Meeting (AGM).

David Meek, Chair of the Board of Directors of Sobi, has informed the Nomination Committee of his decision not to stand for re-election at the 2027 AGM.

David Meek has been a member of Sobi's Board and Chair since December 2024 and will continue to serve as Chair for the remainder of his term to May 2027. During his tenure, Sobi has delivered strong growth and shareholder return, expanded access to its medicines through new launches and indication extensions, and strengthened its clinical development pipeline, supporting the company's long-term growth ambitions.

Börje Ekholm brings more than 30 years of experience across technology, investment management and international business leadership. He recently stepped down as CEO of Ericsson and has previous CEO experience from Patricia Industries and Investor AB. Börje Ekholm currently serves as Chair of the Board of Trimble Inc. and has recently been appointed to the Board of Nasdaq Inc. effective November 1, 2026. His previous Board assignments include Alibaba, Husqvarna, Nasdaq (Chair), Scania and WM Data (Chair). He is also a board advisor for Mars Inc. and an advisor to the CEO of Ericsson. During his CEO tenure at Investor Börje Ekholm was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International and worked with the company from an owner perspective.

"We are pleased to propose Börje Ekholm as the new Chair of the Sobi Board. Börje has significant global leadership and board experience and is very familiar with the company. The Nomination Committee would like to express our sincere gratitude to David for the strong performance and successful development of the company under his leadership", says Daniel Nodhäll, Chair of the Nomination Committee.

The Nomination Committee's complete proposals will be published in due time before the 2027 AGM.

Sobi®

More about Sobi at sobi.com and LinkedIn .

Image gallery
  1. Home

  2. News & Stories

  3. Image gallery

Welcome to Sobi’s image gallery. Here, you will find official photographs of our executive management, global headquarters, and logos. These assets are available for media and other professional use.

Group - Any -LogotypesManagementOther

David Meek

Chairman of the Board

Guido Oelkers

President and CEO

Guido Oelkers

President and CEO

Henrik Stenqvist

CFO

Sobi HQ building

Stockholm, Sweden

Sobi logo

on house facade

Sobi logo

in EPS format

Sobi logo

in PNG format

Can’t find what you need?

Contact us for specific media assets.
 

Follow us

sobi logo

© Sobi - Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321

About

Who we are

We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. 

Therapeutic areas

Science

Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.

Innovation

Sustainability

Our Contribution

We contribute to societies by improving access to treatment of rare diseases.

News & Stories

News & stories

Here we present our most recent press releases, stories, news articles, and images.

Investors

Investor Relations

Find out more about our business and financial performance. 

Careers

Who We Are

Every day, we work actively to find better ways to understand and meet patient needs.

Global

Global

Global contacts

Europe

Austria

Belgium NL

Belgium FR

Bulgaria

Croatia

Cyprus

Czech Republic

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Italy

Latvia

Lithuania

Luxembourg

Malta

Norway

Poland

Portugal

Romania

Russia

Slovakia

Slovenia

Spain

Sweden

Switzerland DE

Switzerland FR

The Netherlands

Turkey

United Kingdom

Middle East & Africa

Algeria

Bahrain

Egypt

Iraq

Jordan

Kuwait

Lebanon

Libya

Middle East

Morocco

Qatar

Oman

Saudi Arabia

Tunisia

United Arab Emirates

Asia Pacific

Australia

China

Japan

North America

USA

Canada

Search

Close

Close

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Cookies Settings

Accept All Cookies

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Functional Cookies

Functional Cookies Inactive

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Performance Cookies

Performance Cookies Inactive

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies Inactive

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Confirm My Choices

Powered by Onetrust

Prompts

Swedish Orphan Biovitrum (ticker SOBI), listed in Sweden.

ETFs Holding Swedish Orphan Biovitrum

ETF Weight in ETF Shares Market value As of
TDI 0.82% 62,304 $ 2.969M Jun 30, 2026
DWMF 0.60% 4,268 $ 203.739K Jun 30, 2026
FFDI 0.16% 634 $ 31.333K Jul 31, 2026
FFGX 0.16% 1,776 $ 87.772K Jul 31, 2026
IVSI 0.15% 249 $ 11.864K Jun 30, 2026
DFSI 0.09% 20,756 $ 1.01M Nov 12, 2026
JSTC 0.04% 2,703 $ 128.559K Nov 17, 2026
DFAI 0.04% 147,295 $ 7.166M Nov 12, 2026
DXIV 0.03% 1,364 $ 66.358K Nov 12, 2026
DFIC 0.02% 79,106 $ 3.848M Nov 12, 2026
AVDE 0.02% 70,513 $ 3.335M Nov 16, 2026
DFAX 0.02% 48,698 $ 2.369M Nov 12, 2026
FENI 0.02% 33,364 $ 1.59M Jun 30, 2026
DFIV 0.01% 61,586 $ 2.996M Nov 12, 2026